1. Market Research
  2. > Healthcare
  3. > Medical Device
  4. > In Vitro Diagnostics Market Trends
  5. > G Protein-Coupled Receptor 119 (GPR119) Agonists -Pipeline Insights, 2016


DelveInsight’s, “G Protein-Coupled Receptor 119 (GPR119) Agonists-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the G Protein-Coupled Receptor 119 (GPR119) Agonists. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for G Protein-Coupled Receptor 119 (GPR119) Agonists. DelveInsight’s Report also assesses the G Protein-Coupled Receptor 119 (GPR119) Agonists therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitive pipeline landscape of G Protein-Coupled Receptor 119 (GPR119) Agonists
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the G Protein-Coupled Receptor 119 (GPR119) Agonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for G Protein-Coupled Receptor 119 (GPR119) Agonists and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

G Protein-Coupled Receptor 119 (GPR119) Agonists -Pipeline Insights, 2016

- G Protein-Coupled Receptor 119 (GPR119) Agonists Overview
- G Protein-Coupled Receptor 119 (GPR119) Agonists Disease Associated
- G Protein-Coupled Receptor 119 (GPR119) Agonists Pipeline Therapeutics
- G Protein-Coupled Receptor 119 (GPR119) Agonists Therapeutics under Development by Companies
- G Protein-Coupled Receptor 119 (GPR119) Agonists Filed and Phase III Products
- Comparative Analysis
- G Protein-Coupled Receptor 119 (GPR119) Agonists Phase II Products
- Comparative Analysis
- G Protein-Coupled Receptor 119 (GPR119) Agonists Phase I and IND Filed Products
- Comparative Analysis
- G Protein-Coupled Receptor 119 (GPR119) Agonists Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- G Protein-Coupled Receptor 119 (GPR119) Agonists - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- G Protein-Coupled Receptor 119 (GPR119) Agonists - Discontinued Products
- G Protein-Coupled Receptor 119 (GPR119) Agonists - Dormant Products
- Companies Involved in Therapeutics Development for G Protein-Coupled Receptor 119 (GPR119) Agonists
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for G Protein-Coupled Receptor 119 (GPR119) Agonists by Therapy Area, 2016
- Number of Products under Development for G Protein-Coupled Receptor 119 (GPR119) Agonists, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- G Protein-Coupled Receptor 119 (GPR119) Agonists Assessment by Monotherapy Products
- G Protein-Coupled Receptor 119 (GPR119) Agonists Assessment by Combination Products
- G Protein-Coupled Receptor 119 (GPR119) Agonists Assessment by Route of Administration
- G Protein-Coupled Receptor 119 (GPR119) Agonists Assessment by Stage and Route of Administration
- G Protein-Coupled Receptor 119 (GPR119) Agonists Assessment by Molecule Type
- G Protein-Coupled Receptor 119 (GPR119) Agonists Assessment by Stage and Molecule Type
- G Protein-Coupled Receptor 119 (GPR119) Agonists Therapeutics - Discontinued Products
- G Protein-Coupled Receptor 119 (GPR119) Agonists Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for G Protein-Coupled Receptor 119 (GPR119) Agonists by Therapy Area, 2016
- Number of Products under Development for G Protein-Coupled Receptor 119 (GPR119) Agonists, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- G Protein-Coupled Receptor 119 (GPR119) Agonists Assessment by Monotherapy Products
- G Protein-Coupled Receptor 119 (GPR119) Agonists Assessment by Combination Products
- G Protein-Coupled Receptor 119 (GPR119) Agonists Assessment by Route of Administration
- G Protein-Coupled Receptor 119 (GPR119) Agonists Assessment by Stage and Route of Administration
- G Protein-Coupled Receptor 119 (GPR119) Agonists Assessment by Molecule Type
- G Protein-Coupled Receptor 119 (GPR119) Agonists Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...

2016 Europe Microbiology Analyzers and Reagents in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnosti

2016 Europe Microbiology Analyzers and Reagents in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnosti

  • $ 30000
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 28-country survey from VPGMarketResearch.com contains over 820 pages and 418 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...

Hematology and Flow Cytometry: A Market Facing Regulatory and Competitive Challenges--Advances in Molecular Diagnostics, IT, and Growing Understanding of Immunologic Forces Regulating Systemic Diseases Will Profoundly Impact the Market

Hematology and Flow Cytometry: A Market Facing Regulatory and Competitive Challenges--Advances in Molecular Diagnostics, IT, and Growing Understanding of Immunologic Forces Regulating Systemic Diseases Will Profoundly Impact the Market

  • $ 15900
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $24,500.  DataPack (test volumes, sales forecasts, supplier shares) $15,900. VPGMarketResearch’s new seven-country report is designed to help current suppliers and potential market ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.